PLANTATION, Fla., Oct. 7, 2013 /PRNewswire/ -- Neurotrope, Inc. (formerly BlueFlash Communications, Inc.) (NTRP), a Nevada corporation (the "Company"), announced today that it has formally hired Robert Weinstein to be its Executive Vice President and Chief Financial Officer.  Mr. Weinstein had been the acting Chief Financial Officer, as a consultant, since May 2013 and was instrumental in executing the Company's private financings and reverse merger, which both closed in August 2013.<br /><br />Prior to joining Neurotrope, Mr. Weinstein was a financial and accounting consultant to several healthcare companies in the pharmaceutical, medical device and biotechnology industries.  Prior to his consulting roles, Mr. Weinstein was the Chief Financial Officer of three publicly traded companies, consistently increasing shareholder value through an active role in investor relations while partnering with senior management to provide strategic guidance and leading all Securities and Exchange Commission filing compliance.  Prior to his senior officer and consulting positions, Mr. Weinstein was a founding partner in a highly successful healthcare-oriented private equity fund and an investment banker focused on micro-cap company financings and mergers & acquisitions.<br /><br />He is a certified public accountant and earned his Masters of Business Administration at The University of Chicago Graduate School of Business.<br /><br />About Neurotrope<br /><br />Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage.  Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions.  These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization.  In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.<br /><br />Please visit www.neurotropebioscience.com for further information.